VYNE Therapeutics Inc.
VYNE
$0.59
$0.000.66%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 59.77% | 40.12% | 38.82% | -37.80% | -94.28% |
| Total Depreciation and Amortization | 25.00% | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 185.06% | 47.16% | 17.10% | 112.08% | -66.23% |
| Change in Net Operating Assets | -78.05% | -104.65% | -919.69% | -69.93% | 381.51% |
| Cash from Operations | 58.17% | 16.62% | -27.36% | -43.60% | -75.18% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -34.19% | 191.25% | -75.42% | 655.65% | 120.62% |
| Cash from Investing | -33.58% | 191.25% | -75.42% | 655.65% | 120.43% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 88.64% | -250.00% | -1,600.00% | -1,640.00% | -6,500.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 88.64% | -250.00% | -1,600.00% | -1,640.00% | -100.16% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 29.78% | 79.75% | -158.49% | 171.68% | -76.23% |